<DOC>
	<DOCNO>NCT02497547</DOCNO>
	<brief_summary>Up 50 % postmenopausal woman frequently suffer atrophic vaginitis vaginal atrophy symptom include vaginal dryness , irritation , burning , itch discomfort . Vaginal atrophy consequence line tissue vagina become thinner , dry , less elastic due lack estrogen . In addition , vaginal atrophy associate increase pH , create environment susceptible infection . Menopausal hormone therapy common treatment vaginal atrophy . However , menopausal hormone therapy show coincide increase incidence breast cancer , heart attack stroke . Some woman experience adverse reaction uterine bleeding , perineal pain , breast pain menopausal hormone therapy . Many woman also reluctant initiate estrogen treatment , due general negative view menopausal hormone therapy society . There also many contraindicate condition like undiagnosed vaginal bleeding , thromboembolic disease , breast cancer , estrogen-sensitive cancer , liver disease . Women suffer vaginal atrophy present condition extremely limit option effective therapy . Oxytocin peptide hormone , normally release circulation via pituitary . Oxytocin show vitro exert positive effect proliferation human vaginal mucosal cell postmenopausal woman . Local application oxytocin , form vaginal gel , Vagitocin , investigate previous study postmenopausal woman , new effective safe option treatment vaginal atrophy . Vagitocin appear reverse manifestation vaginal atrophy stimulate vaginal mucosal growth , reduce symptom vaginal atrophy increase patient ' wellbeing quality life . Overall , treatment Vagitocin safe well tolerated subject study . In study , clinical efficacy Vagitocin potential treatment postmenopausal woman suffer moderate severe symptom vaginal atrophy , vaginal irritation/itching vaginal discomfort and/or pain associate sexual activity explore . In addition , dose relationship low effective dose Vagitocin investigate .</brief_summary>
	<brief_title>An Efficacy Study Vagitocin Postmenopausal Women With Symptoms Vaginal Atrophy</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Oxytocin</mesh_term>
	<criteria>To participate study , subject must : 1 . Be female subject age 40 65 year time randomization , willing participate study indicate sign informed consent 2 . Be postmenopausal woman least 24 month spontaneous amenorrhea woman , surgical bilateral oophorectomy without hysterectomy least 6 week ago 3 . Have ≤ 5 % superficial cell vaginal smear cytology screen 4 . Have vaginal pH &gt; 5.0 screen 5 . Have level estradiol ≤ 30 pg/mL level Follicle Stimulating Hormone ( FSH ) &gt; 40 milli International Units ( mIU ) /ml screen 6 . Have one moderate severe vaginal atrophy symptom ( vaginal irritation itching , dyspareunia , vaginal dryness , dysuria presence vaginal bleeding associate sexual activity ) identify subject bothersome 7 . Have Body Mass Index ( BMI ) ≤32 kg/m2 8 . Be judge Principal Investigator Subinvestigator otherwise good health base prestudy medical evaluation perform within 35 day prior initial dose study medication 9 . Have endometrial thickness &lt; 4 mm determine vaginal ultrasonography , woman intact uterus 10 . Be willing abstain sexual activity use vaginal douching within 24 hour prior vaginal pH measurement screen Visits 2 3 To participate study , subject must : 1 . Be currently hospitalize 2 . Have history ongoing cardiovascular , hepatic , renal , pulmonary , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychological , musculoskeletal disease disorder clinically significant opinion Principal Investigator SubInvestigator 3 . Have know suspected tumor disease clinically significant opinion Principal Investigator SubInvestigator 4 . Have history endometrial hyperplasia uterine/endometrial , breast ovarian cancer 5 . Have history undiagnosed vaginal bleeding 6 . Have ongoing urogenital infection randomization visit 7 . Any contraindication oxytocin therapy allergy use oxytocin component investigational drug 8 . Have history drug and/or alcohol abuse within one year start study 9 . Have use prescription Over The Counter ( OTC ) medication include phytoestrogens , herbal medicinal product hormonal intrauterine device know estrogenic effect within 12 week prior screen procedure 10 . Have use type vaginal lubricant moisturizers within 24 hour prior screen procedure 11 . Have use estrogen alone estrogen/progestin time period specify protocol 12 . Have reason , opinion Principal Investigator SubInvestigator would prevent subject safely participate study comply protocol requirement 13 . Have participate another clinical trial within 90 day prior screen , receive investigational drug within three month prior initial dose study medication , likely participate clinical trial receive another investigational medication study 14 . Have contraindication plan study procedure</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Atrophy</keyword>
	<keyword>Pathological Conditions , Anatomical</keyword>
	<keyword>Oxytocin</keyword>
	<keyword>Oxytocics</keyword>
</DOC>